A Phase 4 interventional study of decitabine and azacitidine in Myelodysplastic Syndromes, sponsored by Eisai Inc.. Terminated at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-29.
Sponsored by Eisai Inc. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies testing decitabine in Myelodysplastic Syndromes — 9 open to participants now, 16 under way, 1 of them phase 3. Decitabine · Myelodysplastic Syndromes.
Among the 75 studies testing decitabine in Myelodysplastic Syndromes, this one is the 46th largest by enrollment of the 74 interventional ones that give a count, is one of 7 that started in 2009, is one of 3 in phase 4, and was the 29th registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
Browse Myelodysplastic Syndromes studies →9 of the 75 studies testing decitabine in Myelodysplastic Syndromes are open now, in 3 countries. Recruiting first, the newest first:
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+ · Healthy volunteers
West Virginia University · Sites in United States
Ages 18+
Beijing 302 Hospital · Sites in China
Ages 18–70
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 60+
Clinical Hub for Interventional Research (CHOIR) · Sites in Australia
Ages 18+
By country, each count listing its studies:
Decitabine: first FDA approval 2006 (DACOGEN), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 49 · Phase 3 6 · Phase 4 3
First in 1995; this study’s year is marked. 7 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 43 across the 74 interventional studies. Of the 48 that completed or were terminated, 29 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 75 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
Eisai Co., Ltd. has 7 studies filed under Myelodysplastic Syndromes — fewer than ten, so there is no comparison to draw.
2 of the studies testing decitabine in Myelodysplastic Syndromes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06923488West Virginia UniversityLeflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes | 2027-10 |
| NCT04282187University of WashingtonDecitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | 2027-11-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 75 studies testing decitabine in Myelodysplastic Syndromes, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the response of patients with Intermediate or High Risk myelodysplastic syndromes (MDS) following treatment with decitabine or azacitidine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects who meet all of the following criteria may be included in the study:
Exclusion Criteria
Subjects who meet any of the following criteria will be excluded from participation in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: decitabine
Drug: azacitidine
decitabine 20 mg/m\^2 /day intravenous (IV) infusion for 5 days every 28 days
Also known as: Dacogen (decitabine)
azacitidine 75 mg/m\^2 /day subcutaneous (SC) injection for 7 days every 28 days
Also known as: Vidaza (azacitidine)
Overall Response Rate (ORR), Defined as Proportion of Patients Having Complete Response (CR) and Marrow Complete Response (mCR) After Completion of 3 Cycles of Study Drug.
Based on Modified International Working Group Response Criteria for Altering Natural History of Myelodysplastic Syndromes. Complete Response: Bone marrow: ≤ 5% myeloblasts with normal maturation of all cell lines. Persistent dysplasia will be noted. Peripheral blood Hgb ≥ 11 g/dL; Platelets ≥ 100 X 10\^9/L; Neutrophils ≥ 1.0 X 10\^9/Lb; Blasts 0%. Marrow Complete Response: Bone marrow: ≤ 5% myeloblasts and decrease by ≥ 50% over pretreatment. Peripheral blood: if hematological improvement responses, they will be noted in addition to marrow CR.
Time frame: 13 Weeks
Overall Response Rate (ORR), Defined as Proportion of Patients Having Complete Response (CR) and Marrow Complete Response (mCR) After Completion of 6 Cycles of Study Drug.
Based on Modified International Working Group Response Criteria for Altering Natural History of Myelodysplastic Syndromes. Complete Response: Bone marrow: ≤ 5% myeloblasts with normal maturation of all cell lines. Persistent dysplasia will be noted. Peripheral blood Hgb ≥ 11 g/dL; Platelets ≥ 100 X 10\^9/L; Neutrophils ≥ 1.0 X 10\^9/Lb; Blasts 0%. Marrow Complete Response: Bone marrow: ≤ 5% myeloblasts and decrease by ≥ 50% over pretreatment. Peripheral blood: if hematological improvement responses, they will be noted in addition to marrow CR.
Time frame: 36 Weeks
This study was recruited at 20 centers in U.S. during the period of Feb 2010 to Jan 2011.
| Milestone | Decitabine 20 mg/m^2 | Azacitidine 75 mg/m^2 |
|---|---|---|
| Started | 13 | 13 |
| Completed | 2 | 2 |
| Not completed | 11 | 11 |
| Withdrew: Adverse event | 4 | 2 |
| Withdrew: Progressive disease | 0 | 2 |
| Withdrew: Terminated by sponsor | 5 | 5 |
| Withdrew: Other | 2 | 2 |
Based on Modified International Working Group Response Criteria for Altering Natural History of Myelodysplastic Syndromes. Complete Response: Bone marrow: ≤ 5% myeloblasts with normal maturation of all cell lines. Persistent dysplasia will be noted. Peripheral blood Hgb ≥ 11 g/dL; Platelets ≥ 100 X 10\^9/L; Neutrophils ≥ 1.0 X 10\^9/Lb; Blasts 0%. Marrow Complete Response: Bone marrow: ≤ 5% myeloblasts and decrease by ≥ 50% over pretreatment. Peripheral blood: if hematological improvement responses, they will be noted in addition to marrow CR.
| Percentage of Participants | Decitabine 20 mg/m^2 | Azacitidine 75 mg/m^2 |
|---|---|---|
| Overall Response Rate | 0 | 0 |
| Complete Response | 0 | 0 |
| Marrow Complete Response | 0 | 0 |
| Partial Response | 0 | 0 |
| Stable Disease | 45.5 | 25.0 |
Based on Modified International Working Group Response Criteria for Altering Natural History of Myelodysplastic Syndromes. Complete Response: Bone marrow: ≤ 5% myeloblasts with normal maturation of all cell lines. Persistent dysplasia will be noted. Peripheral blood Hgb ≥ 11 g/dL; Platelets ≥ 100 X 10\^9/L; Neutrophils ≥ 1.0 X 10\^9/Lb; Blasts 0%. Marrow Complete Response: Bone marrow: ≤ 5% myeloblasts and decrease by ≥ 50% over pretreatment. Peripheral blood: if hematological improvement responses, they will be noted in addition to marrow CR.
| Percentage of Participants | Decitabine 20 mg/m^2 | Azacitidine 75 mg/m^2 |
|---|---|---|
| Overall Response Rate | 9.1 | 8.3 |
| Complete Response | 9.1 | 8.3 |
| Marrow Complete Response | 0 | 0 |
| Partial Response | 9.1 | 0 |
| Stable Disease | 36.4 | 16.7 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Decitabine 20 mg/m^2 | — | 7/13 (53.8%) | 13/13 (100%) |
| Azacitidine 75 mg/m^2 | — | 7/13 (53.8%) | 13/13 (100%) |
| Event | Decitabine 20 mg/m^2 | Azacitidine 75 mg/m^2 |
|---|---|---|
| PancytopeniaBlood and lymphatic system disorders | 3/13 | 1/13 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/13 | 2/13 |
| ThrombocytopeniaCardiac disorders | 2/13 | 0/13 |
| PneumoniaInfections and infestations | 2/13 | 0/13 |
| AnemiaBlood and lymphatic system disorders | 1/13 | 1/13 |
| AspergillosisInfections and infestations | 1/13 | 0/13 |
| Neutropenia sepsisInfections and infestations | 0/13 | 1/13 |
| DiverticulitisInfections and infestations | 0/13 | 1/13 |
| SepsisInfections and infestations | 1/13 | 0/13 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/13 | 0/13 |
| Event | Decitabine 20 mg/m^2 | Azacitidine 75 mg/m^2 |
|---|---|---|
| NauseaGastrointestinal disorders | 1/13 | 9/13 |
| VomitingGastrointestinal disorders | 0/13 | 8/13 |
| AnemiaBlood and lymphatic system disorders | 7/13 | 5/13 |
| FatigueGeneral disorders | 5/13 | 7/13 |
| NeutropeniaBlood and lymphatic system disorders | 6/13 | 6/13 |
| ThrombocytopeniaBlood and lymphatic system disorders | 6/13 | 5/13 |
| DiarrheaGastrointestinal disorders | 4/13 | 5/13 |
| LeukopeniaBlood and lymphatic system disorders | 4/13 | 3/13 |
| Injection site erythemaGeneral disorders | 0/13 | 4/13 |
| Injection site reactionGeneral disorders | 0/13 | 4/13 |
| Age, Continuous(years) | Decitabine 20 mg/m^2 | Azacitidine 75 mg/m^2 | Total |
|---|---|---|---|
| Mean | 73.8 ± 11.60 | 70.8 ± 9.13 | 72.3 ± 10.35 |
| Sex: Female, Male(Participants) | Decitabine 20 mg/m^2 | Azacitidine 75 mg/m^2 | Total |
|---|---|---|---|
| Female | 2 | 3 | 5 |
| Male | 11 | 10 | 21 |
| Ethnicity (NIH/OMB)(Participants) | Decitabine 20 mg/m^2 | Azacitidine 75 mg/m^2 | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 |
| Not Hispanic or Latino | 13 | 11 | 24 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Decitabine 20 mg/m^2 | Azacitidine 75 mg/m^2 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 13 | 12 | 25 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
The record gives a start of Nov 2009 and a primary completion of Jan 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2013, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Decitabine · Azacitidine